Amphista Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $16.9M

  • Investors
  • 9

Amphista Therapeutics General Information

Description

Developer of next-generation targeted protein degradation therapeutics designed to treat a range of diseases. The company's therapeutics advance novel approaches in targeted protein degradation to create a new generation of therapies with improved efficacy and identify the cell's degradation machinery to modulate the abundance of proteins that are responsible for disease progression, enabling healthcare providers to improve the lives of patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Cori Building
  • Granta Park, Great Abington
  • Cambridge CB21 6GQ
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • The Cori Building
  • Granta Park, Great Abington
  • Cambridge CB21 6GQ
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amphista Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 24-Oct-2025 $16.9M Completed Pre-Clinical Trials
5. Early Stage VC (Series B) 17-Mar-2021 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 07-Apr-2020 Completed Pre-Clinical Trials
3. Seed Round Completed Startup
2. Accelerator/Incubator 01-Jan-2020 $65.6K $65.6K Completed Startup
1. University Spin-Out 20-Dec-2017 Completed Startup
To view Amphista Therapeutics’s complete valuation and funding history, request access »

Amphista Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series B
Series B
Series B
Series A 913,332 $0.000134 $1.21 $1.21 1x $1.21 3.69%
Series A 5,829,062 $0.000134 $1.34 $1.34 1x $1.34 23.57%
To view Amphista Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Amphista Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of next-generation targeted protein degradation therapeutics designed to treat a range of diseases. The compan
Drug Discovery
Cambridge, United Kingdom
65 As of 2025

Boston, MA
 

Watertown, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amphista Therapeutics Competitors (4)

One of Amphista Therapeutics’s 4 competitors is Catamaran Bio, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Catamaran Bio Venture Capital-Backed Boston, MA
Kymera Therapeutics Formerly VC-backed Watertown, MA
Cullgen Formerly VC-backed San Diego, CA
Nurix Therapeutics Formerly VC-backed San Francisco, CA
To view Amphista Therapeutics’s complete competitors history, request access »

Amphista Therapeutics Patents

Amphista Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202509684-D0 Compounds for first line therapy Pending 18-Jun-2025
GB-202509687-D0 Compounds for targeted protein degradation Pending 18-Jun-2025
GB-202509688-D0 Compounds for targeted protein degradation Pending 18-Jun-2025
GB-202509690-D0 Compounds for treating resistant patients Pending 18-Jun-2025
GB-202509686-D0 Pharmaceutical combinations Pending 18-Jun-2025
To view Amphista Therapeutics’s complete patent history, request access »

Amphista Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amphista Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Eli Lilly and Company Foundation Limited Partner Minority
Forbion Venture Capital Minority
Gilde Healthcare PE/Buyout Minority
Novartis Venture Fund Corporate Venture Capital Minority
SV Health Investors PE/Buyout Minority
You’re viewing 5 of 9 investors. Get the full list »

Amphista Therapeutics FAQs

  • When was Amphista Therapeutics founded?

    Amphista Therapeutics was founded in 2017.

  • Where is Amphista Therapeutics headquartered?

    Amphista Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Amphista Therapeutics?

    Amphista Therapeutics has 65 total employees.

  • What industry is Amphista Therapeutics in?

    Amphista Therapeutics’s primary industry is Drug Discovery.

  • Is Amphista Therapeutics a private or public company?

    Amphista Therapeutics is a Private company.

  • What is the current valuation of Amphista Therapeutics?

    The current valuation of Amphista Therapeutics is .

  • What is Amphista Therapeutics’s current revenue?

    The current revenue for Amphista Therapeutics is .

  • How much funding has Amphista Therapeutics raised over time?

    Amphista Therapeutics has raised $78.5M.

  • Who are Amphista Therapeutics’s investors?

    Eli Lilly and Company Foundation, Forbion, Gilde Healthcare, Novartis Venture Fund, and SV Health Investors are 5 of 9 investors who have invested in Amphista Therapeutics.

  • Who are Amphista Therapeutics’s competitors?

    Catamaran Bio, Kymera Therapeutics, Cullgen, and Nurix Therapeutics are competitors of Amphista Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process